More Articles Back to Article

Partnership to advance SARS-CoV-2 vaccine in Japan

MediciNova has signed a SARS-CoV-2 vaccine development deal that will use BC-PIV, a human parainfluenza virus type 2 vector created by BioComo and Mie University, with MediciNova gaining exclusive rights to global development of the vaccine. Seeking Alpha (free registration) (7/27)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!